Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice

Cardiovascular Therapeutics
Hyunah KimHun-Sung Kim

Abstract

Prescription of statins to patients with chronic liver disease whose alanine transaminase (ALT) is over three times the upper normal limit (UNL) is not recommended. In this study, we attempted to evaluate patients with baseline ALT levels > 3 ×  UNL who were prescribed statins without ethical problems, using electronic medical records. We enrolled subjects with ALT levels > 3 ×  UNL. The patients were divided into three groups consisting of those who had been taking agents affecting liver function (HEPA) and continued to do so after the statin prescription (HepCon), those who had not previously taken HEPA and began doing so after statin prescription (HepNew), and those who had never taken HEPA (HepNo). All ALT levels were determined within 3 months of statins administration, and changes were monitored. From January 2009 to December 2012, 61 patients with baseline ALT levels > 3 ×  UNL were prescribed statins for the first time. During the 3-month ALT monitoring, levels of the HepCon, HepNew, and HepNo groups decreased by 45 ± 8%, 64 ± 10%, and 42 ± 8%, respectively; however, intergroup differences were not significant (P = .386). All the subjects who were administered statins showed improvement or maintained their ALT levels, e...Continue Reading

References

Aug 12, 1999·The New England Journal of Medicine·R H Knopp
Jun 20, 2000·The American Journal of Cardiology·K G Tolman
Sep 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·J A Farmer, G Torre-Amione
Nov 3, 2004·The American Journal of Cardiology·Allan D Sniderman
Feb 24, 2007·The American Journal of Cardiology·James S Forrester, Peter Libby
Aug 29, 2007·Clinics in Liver Disease·Sidharth S Bhardwaj, Naga Chalasani
Jul 31, 2008·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Curtis K ArgoAmedeo Lonardo
Nov 18, 2008·Metabolism: Clinical and Experimental·Hideyuki HyogoKazuaki Chayama
Oct 1, 2010·The New England Journal of Medicine·Giovanni TargherEnzo Bonora
May 9, 2012·Heart Views : the Official Journal of the Gulf Heart Association·Pranav SikkaSeema Kapoor
Jun 22, 2012·The American Journal of Cardiology·Antonio M Gotto, Jennifer E Moon
Jan 10, 2014·Diabetes & Metabolism Journal·Ji Sung Yoon, Hyoung Woo Lee
May 6, 2014·Journal of Clinical Lipidology·Harold Bays The National Lipid Association's Statin Safety Task Force
Apr 30, 2015·Diabetes & Metabolism Journal·Chang Ho Ahn, Sung Hee Choi
Aug 19, 2015·Healthcare Informatics Research·Kyoung Won ChoYoung Moon Chae
May 21, 2016·Healthcare Informatics Research·Jae-Young ChoiJinhyung Lee
Mar 4, 2017·Endocrinology and Metabolism·Hun Sung KimKun Ho Yoon

❮ Previous
Next ❯

Citations

Jun 9, 2018·Cardiovascular Therapeutics·Vasilios G AthyrosDimitri P Mikhailidis
Jan 4, 2020·Journal of Korean Medical Science·Hun Sung Kim

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nihon rinsho. Japanese journal of clinical medicine
Taku Yamamura, Masato Ishigami
Circulation
Christopher HeeschenPlatelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators
© 2022 Meta ULC. All rights reserved